Cinnamtannin A2, a tetrameric procyanidin, enhances GLP-1 and insulin secretion in mice while also upregulating the expression of corticotrophin releasing hormone. Additionally, Cinnamtannin A2 exhibits antioxidant, anti-diabetic, and nephroprotective effects.

Cinnamtannin A2 (0.125-2.0 μg/mL) inhibits LDL oxidation induced by copper ions or MeO-AMVN[3].

Cinnamtannin A2 (10 mg/kg; i.p. for 30 days) ameliorates the level of KIM1 and NAGL in 5/6 nephractomized rats by regulating Nrf2- Keap1 pathway[2]. Cinnamtannin A2 (10 μg/kg; p.o.) increases the secretion of insulin and glucagon-like peptide-1 (GLP-1) in plasma of mice[1]. Cinnamtannin A2 (10 μg/kg; p.o.) significantly promotes phosphorylation of both IRB and IRS-1 in mice[1]. Animal Model: Male Sprague-Dawley rats (250-300 g) were induced chronic renal failure (CRF) by removing the kidneys[2]Dosage: 10 mg/kg Administration: I.p. for 30 days Result: Ameliorated the altered level of creatinine, blood urea nitrogen, Neutrophil gelatinase-associated lipocalin, Kidney Injury Molecule-1 and cytokines in the serum and microalbuminurea. Reduced the oxidative stress level. Attenuated the altered expression of proteins involved in Nrf2-Keap1 pathway in the kidney tissue. Reduced the tubular injury score in the kidney tissue.